Stockreport

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc.  (OTLK) 
Last outlook therapeutics, inc. earnings: 2/14 08:00 am Check Earnings Report
PDF ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the Europea [Read more]